Latigo Biotherapeutics (LTGO) Stock Analysis

What Latigo Biotherapeutics does

Latigo Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its products include Molecule: LTG-001, Molecule: LTG-32, Molecule: LTG-001 IV and Molecule: LTG-418. The company was founded on November 20, 2018 and is headquartered in Thousand Oak, CA.

Key metrics

ETFs linked to LTGO

Broad-market and Healthcare sector ETFs an investor holding Latigo Biotherapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how LTGO fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Latigo Biotherapeutics?

Latigo Biotherapeutics trades under the ticker LTGO on NASDAQ.

Which exchange is LTGO listed on?

LTGO is listed on NASDAQ.

What sector does Latigo Biotherapeutics operate in?

Latigo Biotherapeutics is classified in the Healthcare sector (Medical - Pharmaceuticals industry).

How can PortView help analyze LTGO in a portfolio?

PortView shows LTGO's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.